Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

An introduction to overviews of reviews: planning a relevant research question and objective for an overview.

Hunt H, Pollock A, Campbell P, Estcourt L, Brunton G.

Syst Rev. 2018 Mar 1;7(1):39. doi: 10.1186/s13643-018-0695-8.

2.

The Alteration of Irisin-Brain-Derived Neurotrophic Factor Axis Parallels Severity of Distress Disorder in Bronchial Asthma Patients.

Szilasi ME, Pak K, Kardos L, Varga VE, Seres I, Mikaczo A, Fodor A, Szilasi M, Tajti G, Papp C, Gesztelyi R, Zsuga J.

Front Neurosci. 2017 Nov 23;11:653. doi: 10.3389/fnins.2017.00653. eCollection 2017.

3.

Tiotropium in asthma: back to the future of anticholinergic treatment.

Bonini M, Scichilone N.

Clin Mol Allergy. 2017 Dec 4;15:20. doi: 10.1186/s12948-017-0076-1. eCollection 2017. Review.

4.

Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype.

Joshi R, Valdez D, Kim H, Eikenburg DC, Knoll BJ, Bond RA.

Pulm Pharmacol Ther. 2017 Oct;46:30-40. doi: 10.1016/j.pupt.2017.07.004. Epub 2017 Jul 17.

PMID:
28729042
5.

Management of Severe Asthma before Referral to the Severe Asthma Specialist.

Carr TF, Kraft M.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):877-886. doi: 10.1016/j.jaip.2017.04.027. Review.

PMID:
28689838
6.

The evidence on tiotropium bromide in asthma: from the rationale to the bedside.

Radovanovic D, Santus P, Blasi F, Mantero M.

Multidiscip Respir Med. 2017 May 4;12:12. doi: 10.1186/s40248-017-0094-3. eCollection 2017. Review. Erratum in: Multidiscip Respir Med. 2017 Jun 1;12 :17.

7.

Inhaled β2-agonists in asthma management: an evolving story.

Silva D, Jacinto T.

Breathe (Sheff). 2016 Dec;12(4):375-377. doi: 10.1183/20734735.017116.

9.

Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy.

Albertson TE, Bullick SW, Schivo M, Sutter ME.

Drug Des Devel Ther. 2016 Dec 14;10:4047-4060. doi: 10.2147/DDDT.S113573. eCollection 2016. Review.

10.

The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.

Lee HW, Kim HJ, Lee CH.

Br J Clin Pharmacol. 2017 Jun;83(6):1166-1175. doi: 10.1111/bcp.13210. Epub 2017 Jan 12. Review.

PMID:
27957746
11.

β2 Agonists.

Billington CK, Penn RB, Hall IP.

Handb Exp Pharmacol. 2017;237:23-40. doi: 10.1007/164_2016_64. Review.

12.

The Danish National Database for Asthma: establishing clinical quality indicators.

Hansen S, Hoffmann-Petersen B, Sverrild A, Bräuner EV, Lykkegaard J, Bodtger U, Agertoft L, Korshøj L, Backer V.

Eur Clin Respir J. 2016 Nov 8;3:33903. doi: 10.3402/ecrj.v3.33903. eCollection 2016. Review.

13.

Beta-Adrenergic Agonists.

Barisione G, Baroffio M, Crimi E, Brusasco V.

Pharmaceuticals (Basel). 2010 Mar 30;3(4):1016-1044. Review.

14.

Inhaled Corticosteroids.

Barnes PJ.

Pharmaceuticals (Basel). 2010 Mar 8;3(3):514-540. Review.

15.

Asthma prescribing, ethnicity and risk of hospital admission: an analysis of 35,864 linked primary and secondary care records in East London.

Hull SA, McKibben S, Homer K, Taylor SJ, Pike K, Griffiths C.

NPJ Prim Care Respir Med. 2016 Aug 18;26:16049. doi: 10.1038/npjpcrm.2016.49.

16.

Modeling the effectiveness of nebulized terbutaline for decompensated chronic obstructive pulmonary disease patients in the emergency department.

Gueho F, Beaune S, Devillier P, Urien S, Faisy C.

Medicine (Baltimore). 2016 Aug;95(32):e4553. doi: 10.1097/MD.0000000000004553.

17.
18.

Common causes of dyspnoea in athletes: a practical approach for diagnosis and management.

Smoliga JM, Mohseni ZS, Berwager JD, Hegedus EJ.

Breathe (Sheff). 2016 Jun;12(2):e22-37. doi: 10.1183/20734735.006416.

19.

Patient perspectives on fluticasone-vilanterol versus other corticosteroid combination products for the treatment of asthma.

Bollmeier SG, Prosser TR.

Patient Prefer Adherence. 2016 May 13;10:825-36. doi: 10.2147/PPA.S83946. eCollection 2016. Review.

20.

Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.

Pera T, Penn RB.

Pharmacol Ther. 2016 Aug;164:82-96. doi: 10.1016/j.pharmthera.2016.04.002. Epub 2016 Apr 23. Review.

Supplemental Content

Support Center